Metastatic Dedifferentiated Liposarcoma

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Metastatic Dedifferentiated Liposarcoma trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 5 trials

RecruitingPhase 3

NCT06422806

Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Diffe…

This phase III trial compares the effect of immunotherapy (pembrolizumab) plus chemotherapy (doxorubicin) to chemotherapy (doxorubicin) alone in treating patien…

United States365 participantsStarted 2024-09-11

Treatment: Biospecimen Collection, Diagnostic Imaging Testing

RecruitingPhase 1

NCT05711615

Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Adv…

This phase I trial tests the safety, side effects, and best dose of combination therapy with liposomal doxorubicin and peposertib in treating patients with sarc…

United States30 participantsStarted 2024-02-06

Treatment: Biopsy Procedure, Biospecimen Collection

RecruitingPhase 1/2

NCT06498648

Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tis…

This phase I/II trial tests the side effects and best dose of abemaciclib when added to gemcitabine and compares the effectiveness of that treatment to the usua…

United States74 participantsStarted 2026-03-18

Treatment: Abemaciclib, Biopsy Procedure

RecruitingPhase 1

NCT05607095

A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferent…

This is an open label study evaluating lifileucel (LN-144) in patients with metastatic uveal melanoma.

United States30 participantsStarted 2022-11-01

Treatment: Lifileucel (LN-144/LN-145)

RecruitingPhase 1/2

NCT06578624

Safety and Preliminary Efficacy of SA53-OS in Patients With Locally Advanced or Metastatic Solid Tumors

The objective of this study is to assess the safety, efficacy, and pharmacokinetics of SA53-OS in adult participants with refractory solid tumors. The study is…

United States70 participantsStarted 2025-03-10

Treatment: SA53-OS (phase 1), SA53-OS (phase 2)

All recent trials (15 shown)

Active — Not RecruitingPhase 2

NCT04668300

Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma

This phase II trial investigates how well oleclumab and durvalumab work in treating patients with sarcoma that has come back (recurrent) or does not respond to…

United States75 participantsStarted 2020-11-26

Treatment: Durvalumab, Oleclumab

Active — Not RecruitingPhase 2

NCT05694871

Testing the Addition of Cemiplimab to Palbociclib for the Treatment of Advanced Dedifferentiated Liposarcoma

This phase II trial compares the effect of treatment with palbociclib alone to treatment with palbociclib plus cemiplimab for treating patients with dedifferent…

United States77 participantsStarted 2023-06-07

Treatment: Palbociclib, Cemiplimab

Metastatic Dedifferentiated Liposarcoma

Trial phase breakdown

Trial status

Actively recruiting — 5 trials

Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Diffe…

Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Adv…

Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tis…

A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferent…

Safety and Preliminary Efficacy of SA53-OS in Patients With Locally Advanced or Metastatic Solid Tumors

All recent trials (15 shown)

Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma

Testing the Addition of Cemiplimab to Palbociclib for the Treatment of Advanced Dedifferentiated Liposarcoma

Trial phase breakdown

Trial status

Actively recruiting — 5 trials

Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Diffe…

Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Adv…

Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tis…

A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferent…

Safety and Preliminary Efficacy of SA53-OS in Patients With Locally Advanced or Metastatic Solid Tumors

All recent trials (15 shown)

Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma

Testing the Addition of Cemiplimab to Palbociclib for the Treatment of Advanced Dedifferentiated Liposarcoma

A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma

Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas

Open-Label Study of the CDK4/6 Inhibitor SPH4336 in Subjects With Locally Advanced or Metastatic Liposarcomas

Phase 1, First-in-human Study of Oral TP-1287 in Patients with Advanced Solid Tumors

Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery

Sirolimus and Cyclophosphamide in Metastatic or Unresectable Myxoid Liposarcoma and Chondrosarcoma

Ph II Cabazitaxel DD Liposarcoma

Efficacy and Safety of Plitidepsin in Patients With Advanced Unresectable or Metastatic, Relapsed/Refractory, Dedifferen…